Metastatic collecting duct carcinoma of the kidney treated with sunitinib by Tazi, El Mehdi et al.
CASE REPORT Open Access
Metastatic collecting duct carcinoma of the
kidney treated with sunitinib
El Mehdi Tazi
1*, Ismail Essadi
1, Mohamed Fadl Tazi
2, Youness Ahellal
2, Hind M’rabti
1 and Hassan Errihani
1
Abstract
Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal
collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a
case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial
response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity
of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of
multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.
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Introduction
Collecting duct carcinoma (CDC) of the kidney, also
known as Bellini duct carcinoma, is a rare variant of renal
cell carcinoma (RCC) arising from the epithelium of the
distal collecting ducts; it accounts for 2% of all RCCs [1].
Clinically, CDC is characterized by an extremely aggressive
phenotype, accompanying metastatic diseases at presenta-
tion in most reported cases; the prognosis ofCDC is there-
fore poor, with approximately 70% of patients dying of
disease progression within 2 years after diagnosis. In fact,
several systemic therapies, including cytokine therapy and
cytotoxic chemotherapy, have failed to achieve favorable
response to metastatic CDC except for very limited cases
[2-7]. Sunitinib is an orally available inhibitor of multiple
receptor tyrosine kinases, including vascular endothelial
growth factor receptor, platelet-derived growth factor
receptor, and others, with direct antitumor and antiangio-
genic activity. Based on impressive outcomes in several
clinical trials, sunitinib has been approved worldwide for
treatment of RCC patients with clear cell histology [8].
Furthermore, significant therapeutic activities of sunitinib
against non-clear cell RCCs, for example papillary and
chromophobe carcinomas, have also been reported in
recent studies [8,9]; however, it remains unknown whether
sunitinib has a therapeutic impact on CDC of the kidney.
Here, we report the first case of a patient with metastatic
CDC of the kidney who had a favorable response to suniti-
nib treatment.
Case report
A 47-year-old man with a 14.1 cm left renal mass
extending into the renal vein and metastases involving
the bilateral lungs and retroperitoneal lymph nodes
were referred to our institution.
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Figure 1 Hematoxylin and eosin staining of tissue sections
from the nephrectomy specimens demonstrating collecting
duct carcinoma (× 400).
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omy was performed. Pathological examination resulted in
diagnosis of this case as CDC with tubulopapillary archi-
tecture consisting of tumor cells with eosinophilic cyto-
plasm and high-grade nuclei (Figure 1). In addition,
immunohistochemical staining was characteristic of CDC;
that is, tumor cells were positive for Ulex Europaeus
agglutinin (Figure 2), cytokeratin 19, 34bE12, epithelial
membrane antigen and focally positive with vimentin [1].
Following radical nephrectomy, this case was treated with
sunitinib rather than systemic chemotherapy, considering
her poor performance status. After 4 courses of sunitinib
therapy with 37,5 mg daily schedule, metastases to the
lungs and left rib decreased by more than 30% compared
with findings before sunitinib treatment (Figure 3). Despite
the favorable effects of sunitinib on metastatic diseases,
pleural effusion appeared to be remarkable after the
administration of sunitinib; however, cytological examina-
tion showed no malignant cells in the pleural fluid. In
addition to pleural effusion, several adverse events asso-
ciated with sunitinib treatment, including appetite loss,
thrombocytopenias, and hypothyroidism, were observed.
Thereafter, disease progression occurred 10 months after
the initiation of sunitinib, and the patient died.
Discussion
B e c a u s eC D Ci sa nu n c o m m o na nd aggressive disease
with extremely poor prognosis, accumulated information
Figure 2 Tumor showed positive staining for Ulex Europaeus
agglutinin.
Figure 3 Metastatic lesion to the right lung and left sixth rib before (A) and after (B) 4 courses of sunitinib treatment.
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therapy for CDC exists except for surgical resection of
localized diseases. To date, however, there have been 14
reported cases of metastatic CDC showing response to
systemic therapy, consisting 9, 2, 1, and 1 who were trea-
ted by gemcitabine plus cisplatin or carboplatin, pacli-
taxel plus carboplatin, gemcitabine plus doxorubicin, and
interferon-a, respectively [2-7]. Considering these find-
ings in addition to the characteristics of CDC similar to
those of urothelial cancer, chemotherapy is the currently
favored approach for patients with metastatic CDC.
In the case presented, because of her poor perfor-
mance status associated with skeletal metastases, it was
judged to be difficult to perform intensive systemic che-
motherapy. Accordingly, she was treated with sunitinib,
which has been regarded as one of the most powerful
agents against metastatic RCC [8], and showed a partial
response to this drug. Recently, the favorable clinical
activity of sunitinib against non-clear cell carcinomas,
including papillary and chromophobe carcinomas, has
also been reported [8,9]; however, this is the first
reported case demonstrating a therapeutic response of
metastatic CDC to sunitinib. Furthermore, a recent
report presented a case of metastatic CDC showing
response to sorafenib [10].
Conclusion
Although the precise molecular mechanism involved in
the antitumor activity of multiple tyrosine kinase inhibi-
tors against CDC remains largely unknown, these find-
ings suggest that the efficacy of these agents, for
example sunitinib and sorafenib, against metastatic CDC
needs to be prospectively evaluated.
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